Decay data measurements on 213Bi using recoil atoms

Radionuclide metrology: confidence in radioactivity measurements

Radionuclides, whether naturally occurring or artificially produced, are readily detected through their particle and photon emissions following nuclear decay. Radioanalytical techniques use the radiation as a looking glass into the composition of materials, thus providing valuable information to various scientific disciplines. Absolute quantification of the measurand often relies on accurate knowledge of nuclear decay data and detector calibrations traceable to the SI units. Behind the scenes of the radioanalytical world, there is a small community of radionuclide metrologists who provide the vital tools to convert detection rates into activity values. They perform highly accurate primary standardisations of activity to establish the SI-derived unit becquerel for the most relevant radionuclides, and demonstrate international equivalence of their standards through key comparisons. The trustworthiness of their metrological work crucially depends on painstaking scrutiny of their methods and the elaboration of comprehensive uncertainty budgets. Through meticulous methodology, rigorous data analysis, performance of reference measurements, technological innovation, education and training, and organisation of proficiency tests, they help the user community to achieve confidence in measurements for policy support, science, and trade. The author dedicates the George Hevesy Medal Award 2020 to the current and previous generations of radionuclide metrologists who have devoted their professional lives to this noble endeavour.

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter 213Bi

Here, we propose tailored lipid liquid-crystalline carriers (cubosomes), which incorporate an anticancer drug (doxorubicin) and complexed short-lived α-emitter (bismuth-213), as a strategy to obtain more effective action toward the cancer cells. Cubosomes were formulated with doxorubicin (DOX) and an amphiphilic ligand (DOTAGA-OA), which forms stable complexes with ²¹³Bi radionuclide. The behavior of DOX incorporated into the carrier together with the chelating agent was investigated, and the drug liberation profile was determined. The experiments revealed that the presence of the DOTAGA-OA ligand affects the activity of DOX when they are incorporated into the same carrier. This unexpected influence was explained based on the results of release studies, which proved the contribution of electrostatics in molecular interactions between the positively charged DOX and negatively charged DOTAGA-OA in acidic and neutral solutions. A significant decrease in the viability of HeLa cancer cells was achieved using sequential cell exposure: first to the radiolabeled cubosomes containing ²¹³Bi complex and next to DOX-doped cubosomes. Therefore, the sequential procedure for the delivery of both drugs encapsulated in cubosomes is suggested for further biological and in vivo studies.

Status of the decay data for medical radionuclides: existing and potential diagnostic γ emitters, diagnostic β+ emitters and therapeutic radioisotopes

Recommended half-lives and specific well-defined emission energies and absolute emission probabilities are important input parameters that should be well-defined to assist in ensuring the diagnostic and therapeutic efficacy of individual radionuclides when applied in the field of nuclear medicine. Bearing in mind the nature of these requirements, approximately one hundred radionuclides have been considered and re-assessed as to whether their decay data are either adequately quantified, or require further in-depth measurements to improve their existing status and merit full re-evaluations of their decay schemes. The primary aim of such a review is to provide sufficient information on the existing and future requirements for such atomic and nuclear data.

Half-life determination of 213Bi and 209Pb by means of Cherenkov counting and detection with a NaI detector

An ²²⁵Ac source was prepared and combined with a dedicated setup to collect recoil atoms which are ejected as a consequence of alpha decay. Some targets were made of acrylic glass and were then placed in custom-built triple-to-double coincidence ratio (TDCR) counters to measure the Cherenkov counting rates as a function of time. Half-lives of ²¹³Bi and ²⁰⁹Pb were derived from the data. In addition, polyethylene films were used as targets to collect recoil atoms. These films were then measured in a well-type NaI detector to detect gamma rays. The analysis of the data yielded an independent result for the half-life of ²¹³Bi. Combining the results of both measurement techniques, T_1/2(²¹³Bi) = (45.60 ± 0.09) min was obtained as a final value for the half-life of ²¹³Bi. The half-life of ²⁰⁹Pb was found to be T_1/2(²⁰⁹Pb) = (195.1 ± 2.6) min.

Measurement of absolute γ-ray emission probabilities in the decay of 227Ac in equilibrium with its progeny

The emission probabilities of γ rays produced in the ²²⁷Ac decay series were determined by high-resolution γ-ray spectrometry of sources with standardised activity. The sources were prepared quantitatively on glass discs by drop deposition of a solution with ²²⁷Ac in radioactive equilibrium with its daughter nuclides. Their activity was measured by a primary standardisation technique based on alpha-particle counting at a defined low solid angle. Four laboratories performed γ-ray spectrometry and derived absolute γ-ray intensities. Mean values were calculated and compared with literature data and the currently recommended evaluated data. New values on certain γ-ray emission probabilities are proposed.

Direct measurement of alpha emission probabilities in the decay of 226Ra

High-resolution alpha-particle spectrometry was performed to determine the main alpha-particle emission probabilities in the decay of ²²⁶Ra. Thin, homogeneous sources were prepared by electrodeposition on stainless steel disks. Alpha spectra with an energy resolution of 20keV were obtained in three laboratories and analysed with different deconvolution algorithms. In two set-ups, a magnet system was used to deflect conversion electrons to avoid their coincidental detection with the alpha particles. Spectra taken at close range without a magnet system yielded biased results which cannot be fully compensated by statistical corrections for coincidence summing. The derived emission probabilities of the three main alpha decays are 94.07 (1)%, 5.93 (1)%, and 0.0059 (15)%, respectively. They are in excellent agreement with calculated values derived from the P(γ+ce) decay scheme balance, which solves the existing discrepancy problem with two previous direct measurements published in literature.

Targeted Radiolabeled Compounds in Glioma Therapy

Malignant gliomas of World Health Organization (WHO) grades II-IV represent the largest entity within the group of intrinsic brain tumors and are graded according to their pathophysiological features with survival times between more than 10 years (WHO II) and only several months (WHO IV). Gliomas arise from astrocytic or oligodendrocytic precursor cells and exhibit an infiltrative growth pattern lacking a clearly identifiable tumor border. The development of effective treatment strategies of the invasive tumor cell front represents the main challenge in glioma therapy. The therapeutic standard consists of surgical resection and, depending on the extent of resection and WHO grade, adjuvant external beam radiotherapy or systemic chemotherapy. Within the last decades, there has been no major improvement of the prognosis of patients with glioma. The consistent overexpression of neurokinin type 1 receptors in gliomas WHO grades II-IV has been used to develop a therapeutic substance P-based targeting system. A substance P-analogue conjugated to the DOTA or DOTAGA chelator has been labeled with different alpha-particle or beta-particle emitting radionuclides for targeted glioma therapy. The radiopharmaceutical has been locally injected into the tumors or the resection cavity. In several clinical studies, the methodology has been examined in adjuvant and neoadjuvant clinical settings. Although no large controlled series have so far been generated, the results of radiolabeled substance P-based targeted glioma therapy compare favorably with standard therapy. Recently, labeling with the alpha particle emitting Bi-213 has been found to be promising due to the high linear energy transfer and the very short tissue range of 0.08 mm. Further development needs to focus on the improvement of the stability of the compound and the application by dedicated catheter systems to improve the intratumoral distribution of the radiopharmaceutical within the prognostically critical infiltrative growing zone of the glioma.

Measurement of the (211)Pb half-life using recoil atoms from (219)Rn decay

The radioactive half-life of (211)Pb was measured, by α-particle counting of samples of radiochemically pure (211)Pb in equilibrium with its α-emitting progeny, (211)Bi and (211)Po. The samples were prepared by the collection of (215)Po recoil atoms from the decay of the (219)Rn decay progeny produced from a (223)Ra sample onto stainless steel discs. The radioactive decay of the (211)Pb was measured utilising a 2π proportional counter operating on the α plateau. A half-life of 36.164 (13)min was determined, which is in agreement with currently available literature. A full uncertainty budget is presented. A recommended half-life of T1/2((211)Pb)=36.161 (17)min has been evaluated from the current literature values.

Improved peak shape fitting in alpha spectra

Peak overlap is a recurrent issue in alpha-particle spectrometry, not only in routine analyses but also in the high-resolution spectra from which reference values for alpha emission probabilities are derived. In this work, improved peak shape formulae are presented for the deconvolution of alpha-particle spectra. They have been implemented as fit functions in a spreadsheet application and optimum fit parameters were searched with built-in optimisation routines. Deconvolution results are shown for a few challenging spectra with high statistical precision. The algorithm outperforms the best available routines for high-resolution spectrometry, which may facilitate a more reliable determination of alpha emission probabilities in the future. It is also applicable to alpha spectra with inferior energy resolution.

²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

Purpose

Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as ⁹⁰Y/¹⁷⁷Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. Alternative treatments for patients with refractory disease are rare. Here we report the first-in-human experience with ²¹³Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters.

Methods

Seven patients with progressive advanced neuroendocrine liver metastases refractory to treatment with ⁹⁰Y/¹⁷⁷Lu-DOTATOC were treated with an intraarterial infusion of ²¹³Bi-DOTATOC, and one patient with bone marrow carcinosis was treated with a systemic infusion of ²¹³Bi-DOTATOC. Haematological, kidney and endocrine toxicities were assessed according to CTCAE criteria. Radiological response was assessed with contrast-enhanced MRI and ⁶⁸Ga-DOTATOC-PET/CT. More than 2 years of follow-up were available in seven patients.

Results

The biodistribution of ²¹³Bi-DOTATOC was evaluable with 440 keV gamma emission scans, and demonstrated specific tumour binding. Enduring responses were observed in all treated patients. Chronic kidney toxicity was moderate. Acute haematotoxicity was even less pronounced than with the preceding beta therapies.

Conclusion

TAT can induce remission of tumours refractory to beta radiation with favourable acute and mid-term toxicity at therapeutic effective doses.

Electronic supplementary material

The online version of this article (doi:10.1007/s00259-014-2857-9) contains supplementary material, which is available to authorized users.

Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series

The half-lives of (221)Fr, (217)At, (213)Bi, (213)Po, and (209)Pb were measured by means of an ion-implanted planar Si detector for alpha and beta particles emitted from weak (225)Ac sources or from recoil sources, which were placed in a quasi-2π counting geometry. Recoil sources were prepared by collecting atoms from an open (225)Ac source onto a glass substrate. The (221)Fr and (213)Bi half-lives were determined by following the alpha particle emission rate of recoil sources as a function of time. Similarly, the (209)Pb half-life was determined from the beta particle count rate. The shorter half-lives of (217)At and (213)Po were deduced from delayed coincidence measurements on weak (225)Ac sources using digital data acquisition in list mode. The resulting values: T1/2((221)Fr)=4.806 (6) min, T1/2((217)At)=32.8 (3)ms, T1/2((213)Bi)=45.62 (6)min, T1/2((213)Po)=3.708 (8) μs, and T1/2((209)Pb)=3.232 (5)h were in agreement only with the best literature data.